INTRODUCTION
In this roundtable discussion leading experts will inform and guide on the safety and efficacy of TROP2-directed ADCs reported at key conferences such as WCLC and ESMO.
Launch Date: December 29, 2023
Release Date: December 29, 2023
Expiration Date: November 30, 2024
TARGET AUDIENCE
Conversations in Advanced NSCLC is designed for healthcare providers who are involved in the clinical care of patients with NSCLC. This may include physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.
LEARNING OBJECTIVES
Upon completion of this enduring material, participants should be able to:
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Review all modules associated with this course.
- Successfully complete the post-test ( accuracy).
- Complete the CME/CE evaluation.
- The estimated time to complete this activity is hour.
- Upon successful completion, your AMA/ANCC certificate will be emailed to you. ACPE credit will be submitted to Rush University Medical Center and posted to CPE Monitor.
ACCREDITATION STATEMENTS
PHYSICIANS
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Joint Providership Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Rush University Medical Center and Practice Point Communications. Rush University Medical Center is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statements
Rush University Medical Center designates this enduring material for a maximum of AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Rush University Medical Center designates this enduring material for a maximum of continuing nursing contact hour(s).
Rush University Medical Center designates this knowledge based enduring material for a maximum of contact hour(s) for pharmacists.
Disclosure Statements/FDA statement
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.
The IPCE identifies the presence or absence of relevant financial relationships for all individuals in control of content including but not limited to planning committee members, course directors, invited presenters/authors, and staff through a standardized disclosure form. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.
Individuals in control of content for this activity have the following relevant financial relationships to disclose and all financial relationships have been mitigated.
DISCLOSURES
Mary Ellen Hand, BSN
Consultant: Pfizer
The speakers and planning committee members listed below have stated they have no significant relationships to disclose.
Jennifer Comerford
Colleen Goodchild
Trevor Christ, PharmD
Nirupama Mulherkar, PhD
FACULTY DISCLOSURES
Benjamin Levy, MD
Advisor/Consultant: Amgen, AstraZeneca, DSI, Gilead, Guardant360, Janssen, Merck, Mirati Therapeutics, Novartis, Pfizer, Takeda
Aaron Lisberg, MD
Research Grant: AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, WindMIL
Advisor/Consultant: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eli-Lilly, G1 Therapeutics, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron, Sanofi group of companies
Alexander Spira, MD, PhD, FACP
Research Grant: Abbvie, ADCT, Alkermes, Amgen, Arch Therapeutics, ArriVent Biopharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, BluPrint Oncology, Boehringer Ingelheim, Bristol-Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gritstone, Ignyta, Incyte, Janssen Oncology, LAM Therapeutics, Loxo, Macrogenics, MedImmune, Medikine, Mersana, Mirati Therapeutics, Nalo Therapeutics, Novartis, Plexxikon, Regeneron, Revolution Medicines, Roche, Rubius, Scorpion Therapeutics, Synthekine, Takeda
Advisor/Consultant: Amgen, Array BioPharma, AstraZeneca/MedImmune, Black Diamond Therapeutics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo/Astra Zeneca, Gritstone Bio, Gritstone Oncology, Incyte, Janssen Research & Development, Jazz Pharmaceuticals, Lilly, Merck, Mersana, Mirati Therapeutics, Novartis, Regeneron, Sanofi, Takeda
Honoraria: Amgen, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, CytomX Therapeutics, Janssen Oncology, Merck, Novartis, Takeda
Stockholder/Options: Eli Lilly
DISCLAIMER
The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center and Practice Point Communications assume no liability for the information herein.
PRIVACY POLICY
The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.
Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
COPYRIGHT INFORMATION
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
HARDWARE/SOFTWARE REQUIREMENTS
Computer:
- Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
- Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
- Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
Software/Browser:
- Windows 7 or above running Internet Explorer 10 or above.
- MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
- A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
Mobile Device:
- Any Apple iPad or iPad Mini running iOS 7.1 or above.
- Android tablets such as the Kindle Fire or Samsung Galaxy S.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by an independent educational grant from Gilead Sciences, Inc.